ArticleBMC infectious diseases2026
Multidimensional analysis of clinical pharmacist intervention impact on hospital length of stay in pulmonary tuberculosis: a random forest-driven retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe optimization of hospital length of stay (LOS) for tuberculosis (TB) patients remains a critical challenge in healthcare management. This study employs advanced machine learning (ML) techniques to analyze the impact of clinical pharmacist intervention on LOS and identify key predictive factors. Methods: We analyzed 467 tuberculosis cases using a sophisticated ML approach with cross-validation. The model incorporated multiple clinical parameters, including pharmacological data and patient characteristics. Statistical significance was assessed using Mann-Whitney U tests and effect size calculations. Causal inference was performed using propensity score matching. Results: The ML model demonstrated modest predictive performance on cross-validation (R² = 0.085, RMSE = 16.93 days). Clinical pharmacist intervention was associated with a significant reduction in LOS (Mann-Whitney U = 22,588, P < 0.001, Cohen’s d = -0.25). The mean LOS for the intervention group was 51.2 ± 17.9 days, compared to 55.3 ± 16.1 days in the control group. Propensity score matching confirmed the causal effect (Average Treatment Effect (ATE) = -3.9 days, 95% CI: -6.2 to -1.6, P = 0.001). Conclusions: Our findings provided strong evidence for the beneficial impact of clinical pharmacist intervention in TB treatment, supported by robust statistical and ML analyses. While the predictive model showed limited performance, the identified predictive factors offer valuable insights for optimizing patient care and resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.